More on the WAG-BIOS deal (previous): BioScrip (BIOS) will come out of the deal considerably...
More on the WAG-BIOS deal (previous): BioScrip (BIOS) will come out of the deal considerably leaner, but will still have its infusion, home health, pharmacy benefit management and cash card businesses. The firm also say that it will continue to service its infusion patient base and managed care customers through its pharmacies. Shares of BIOS are currently halted.
From other sites
at CNBC.com (Oct 29, 2014)
at CNBC.com (May 27, 2014)
at CNBC.com (May 22, 2014)
at CNBC.com (Apr 10, 2014)
at CNBC.com (Apr 8, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs